Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) shares shot up 7.7% during trading on Friday . The stock traded as high as $15.33 and last traded at $15.32. 149 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 198,391 shares. The stock had previously closed at $14.23.
Analysts Set New Price Targets
Separately, HC Wainwright dropped their target price on shares of Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, August 16th.
Get Imago BioSciences alerts:Imago BioSciences Price Performance
The company has a market cap of $533.46 million and a PE ratio of -8.21. The stock has a fifty day moving average price of $16.04 and a 200-day moving average price of $17.41.
Insider Activity at Imago BioSciences
In other news, insider Jennifer Peppe sold 5,598 shares of the company's stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $19.41, for a total value of $108,657.18. Following the transaction, the insider now owns 148,809 shares in the company, valued at approximately $2,888,382.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 8,168 shares of company stock valued at $155,402. Company insiders own 14.90% of the company's stock.Institutional Investors Weigh In On Imago BioSciences
A number of institutional investors have recently modified their holdings of the stock. Metropolitan Life Insurance Co NY acquired a new stake in shares of Imago BioSciences during the 1st quarter valued at about $28,000. Ameritas Investment Partners Inc. lifted its stake in Imago BioSciences by 108.3% in the first quarter. Ameritas Investment Partners Inc. now owns 1,556 shares of the company's stock valued at $30,000 after acquiring an additional 809 shares during the last quarter. Amalgamated Bank bought a new stake in Imago BioSciences in the first quarter worth approximately $41,000. Legal & General Group Plc grew its position in Imago BioSciences by 46.2% in the second quarter. Legal & General Group Plc now owns 6,098 shares of the company's stock worth $81,000 after acquiring an additional 1,926 shares in the last quarter. Finally, Credit Suisse AG acquired a new position in shares of Imago BioSciences during the 2nd quarter worth $119,000. Institutional investors and hedge funds own 99.50% of the company's stock.
About Imago BioSciences
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
Featured Stories
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.